Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Molecular pathogenesis of chronic myelomonocytic leukemia

Molecular pathogenesis of chronic myelomonocytic leukemia Recent insights into the pathophysiology of chronic myelomonocytic leukemia (CMML) have been obtained by the molecular and biological characterization of primary leukemic cells from patients and from animal models. Almost 3 decades ago extensive myeloid colony growth in semisolid cultures without exogenous growth factors was observed as an in vitro characteristic of a subgroup of CMML patients. Recent data suggest that this phenomenon was probably the first indication of an hyperactive RAS signaling pathway in these patients. Although the mutation landscape in CMML is heterogeneous and molecular aberrations in other signaling components can be found in some patients, the RAS pathway seems to play the major pathophysiological role in the majority of CMML patients with myeloproliferation (MP), disease progression and transformation into secondary acute myeloid leukemia (AML). There is also increasing evidence indicating that the MP-CMML is a RAS pathway driven disease which is superimposed onto age-related clonal hematopoiesis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Molecular pathogenesis of chronic myelomonocytic leukemia

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/molecular-pathogenesis-of-chronic-myelomonocytic-leukemia-roeVmxT7yF
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0295-z
Publisher site
See Article on Publisher Site

Abstract

Recent insights into the pathophysiology of chronic myelomonocytic leukemia (CMML) have been obtained by the molecular and biological characterization of primary leukemic cells from patients and from animal models. Almost 3 decades ago extensive myeloid colony growth in semisolid cultures without exogenous growth factors was observed as an in vitro characteristic of a subgroup of CMML patients. Recent data suggest that this phenomenon was probably the first indication of an hyperactive RAS signaling pathway in these patients. Although the mutation landscape in CMML is heterogeneous and molecular aberrations in other signaling components can be found in some patients, the RAS pathway seems to play the major pathophysiological role in the majority of CMML patients with myeloproliferation (MP), disease progression and transformation into secondary acute myeloid leukemia (AML). There is also increasing evidence indicating that the MP-CMML is a RAS pathway driven disease which is superimposed onto age-related clonal hematopoiesis.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 21, 2016

References

  • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    Vardiman, JW; Thiele, J; Arber, DA
  • Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
    Patnaik, MM; Tefferi, A
  • Colony growth characteristics in chronic myelomonocytic leukemia
    Geissler, K; Hinterberger, W; Bettelheim, P; Haas, O; Lechner, K
  • Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells
    Geissler, K; Ohler, L; Födinger, M
  • High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival
    Sagaster, V; Ohler, L; Berer, A
  • Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia
    Wang, J; Liu, Y; Li, Z
  • K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells
    Meter, ME; Díaz-Flores, E; Archard, JA
  • Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus
    Li, Q; Haigis, KM; McDaniel, A
  • Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice
    Parikh, C; Subrahmanyam, R; Ren, R
  • Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor
    Chan, RJ; Leedy, MB; Munugalavadla, V
  • Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder
    Le, DT; Kong, N; Zhu, Y
  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
    Moran-Crusio, K; Reavie, L; Shih, A
  • Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies
    Li, Z; Cai, X; Cai, CL
  • Prognostic score including gene mutations in chronic myelomonocytic leukemia
    Itzykson, R; Kosmider, O; Renneville, A
  • Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
    Patnaik, MM; Wassie, EA; Padron, E
  • Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
    Padron, E
  • Age-related mutations and chronic myelomonocytic leukemia
    Mason, CC; Khorashad, JS; Tantravahi, SK
  • High prevalence of RAS pathway mutations in CMML patients with high colony growth
    Geissler, K; Zopf, A; Jäger, E; Gabriel, C; Bettelheim, P; Valent, P
  • Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors
    Geissler, K; Jäger, E; Barna, A
  • Clinical, hematological, and biologic characteristics in chronic myelomonocytic leukemia patients with a JAK2 V617F mutation
    Geissler, K; Barna, A; Jäger, E
  • RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant
    Ricci, C; Fermo, E; Corti, S
  • High spontaneous in vitro myeloid colony formation in chronic myelomonocytic leukemia is associated with mutations in RASopathy genes, myeloproliferation and inferior prognosis
    Geissler, K; Barna, A; Jäger, E
  • Clinical, hematological, biologic and molecular characteristics in patients who develop acute myeloid leukemia from chronic myelomonocytic leukemia
    Geissler, K; Barna, A; Jäger, E
  • Evolution of chronic myelomonocytic leukemia to myeloproliferative neoplasm
    Bartels, S; Lehmann, U; Büsche, G; Schlue, J; Kreipe, H
  • RAS diseases in children
    Niemeyer, CM
  • Targeting Ras in myeloid leukemias
    Braun, BS; Shannon, K
  • Absence of N‑ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia
    Watzinger, F; Gaiger, A; Karlic, H; Becher, R; Pillwein, K; Lion, T
  • Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
    Tenedini, E; Bernardis, I; Artusi, V
  • Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures
    Estrov, Z; Grunberger, T; Chan, HS; Freedman, MH
  • Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
    Genovese, G; Kähler, AK; Handsaker, RE
  • Age-related clonal hematopoiesis associated with adverse outcomes
    Jaiswal, S; Fontanillas, P; Flannick, J